Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

Jaume Capdevila; Michel Ducreux; Rocio García Carbonero; Enrique Grande; Thorvardur Halfdanarson; Marianne Pavel; Salvatore Tafuto; Staffan Welin; Vicente Valentí; Ramón Salazar

doi:10.1159/000524988

Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

Jaume Capdevila, Michel Ducreux, Rocio García Carbonero, Enrique Grande, Thorvardur Halfdanarson, Marianne Pavel, Salvatore Tafuto, Staffan Welin, Vicente Valentí, Ramón Salazar

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

In May 1982, the US Food and Drug Administration (FDA) approved the use of streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). Thus, this year marks 40 years since that landmark date. This review of streptozotocin to treat panNETs is intended to commemorate this anniversary. A historical perspective of the chemical structure, pharmacokinetics, and mechanism of action of streptozotocin is followed by data from prospective and retrospective clinical studies. The last section of the review addresses the latest aspects and takes note of the prospects that lie ahead on the future horizon of the use of streptozotocin to treat panNETs, including ongoing clinical trials.

Original language	English
Pages (from-to)	1155-1167
Number of pages	13
Journal	Neuroendocrinology
Volume	112
Issue number	12
DOIs	https://doi.org/10.1159/000524988
Publication status	Published - 1 Nov 2022

Keywords

Historical review
Pancreatic neuroendocrine tumors
Streptozotocin

Access to Document

10.1159/000524988

Cite this

@article{3fcdf480e894441d808e90eed608ac09,

title = "Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors",

abstract = "In May 1982, the US Food and Drug Administration (FDA) approved the use of streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). Thus, this year marks 40 years since that landmark date. This review of streptozotocin to treat panNETs is intended to commemorate this anniversary. A historical perspective of the chemical structure, pharmacokinetics, and mechanism of action of streptozotocin is followed by data from prospective and retrospective clinical studies. The last section of the review addresses the latest aspects and takes note of the prospects that lie ahead on the future horizon of the use of streptozotocin to treat panNETs, including ongoing clinical trials.",

keywords = "Historical review, Pancreatic neuroendocrine tumors, Streptozotocin",

author = "Jaume Capdevila and Michel Ducreux and {Garc{\'i}a Carbonero}, Rocio and Enrique Grande and Thorvardur Halfdanarson and Marianne Pavel and Salvatore Tafuto and Staffan Welin and Vicente Valent{\'i} and Ram{\'o}n Salazar",

year = "2022",

month = nov,

day = "1",

doi = "10.1159/000524988",

language = "English",

volume = "112",

pages = "1155--1167",

journal = "Neuroendocrinology",

issn = "0028-3835",

number = "12",

}

TY - JOUR

T1 - Streptozotocin, 1982-2022

T2 - Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

AU - Capdevila, Jaume

AU - Ducreux, Michel

AU - García Carbonero, Rocio

AU - Grande, Enrique

AU - Halfdanarson, Thorvardur

AU - Pavel, Marianne

AU - Tafuto, Salvatore

AU - Welin, Staffan

AU - Valentí, Vicente

AU - Salazar, Ramón

PY - 2022/11/1

Y1 - 2022/11/1

N2 - In May 1982, the US Food and Drug Administration (FDA) approved the use of streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). Thus, this year marks 40 years since that landmark date. This review of streptozotocin to treat panNETs is intended to commemorate this anniversary. A historical perspective of the chemical structure, pharmacokinetics, and mechanism of action of streptozotocin is followed by data from prospective and retrospective clinical studies. The last section of the review addresses the latest aspects and takes note of the prospects that lie ahead on the future horizon of the use of streptozotocin to treat panNETs, including ongoing clinical trials.

AB - In May 1982, the US Food and Drug Administration (FDA) approved the use of streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). Thus, this year marks 40 years since that landmark date. This review of streptozotocin to treat panNETs is intended to commemorate this anniversary. A historical perspective of the chemical structure, pharmacokinetics, and mechanism of action of streptozotocin is followed by data from prospective and retrospective clinical studies. The last section of the review addresses the latest aspects and takes note of the prospects that lie ahead on the future horizon of the use of streptozotocin to treat panNETs, including ongoing clinical trials.

KW - Historical review

KW - Pancreatic neuroendocrine tumors

KW - Streptozotocin

UR - http://www.scopus.com/inward/record.url?scp=85140772855&partnerID=8YFLogxK

U2 - 10.1159/000524988

DO - 10.1159/000524988

M3 - Article

C2 - 35537416

AN - SCOPUS:85140772855

SN - 0028-3835

VL - 112

SP - 1155

EP - 1167

JO - Neuroendocrinology

JF - Neuroendocrinology

IS - 12

ER -

Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

Abstract

Keywords

Access to Document

Other files and links

Cite this